DESCRIPTION Chemically , Meclizine HCl is 1 - ( p - chloro - α - phenylbenzyl ) - 4 - ( m - methylbenzyl ) piperazine dihydrochloride monohydrate .
[ MULTIMEDIA ] C25H27ClN2 .
2 HCl .
H2O M . W . 481 . 88 Meclizine HCI Tablets , USP are available in two different strengths : 12 . 5 mg and 25 mg .
In addition each tablet contains the following inactive ingredients : Colloidal Silicon Dioxide , Croscarmellose Sodium , Lactose Monohydrate , Magnesium Stearate , Microcrystalline Cellulose .
Also , Meclizine HCI Tablets USP , 12 . 5 mg contains FD & C Blue # 1 Aluminum Lake ( 11 - 13 % ) and Meclizine HCI Tablets USP , 25 mg contains D & C Yellow # 10 Aluminum Lake ( 15 - 20 % ) .
[ MULTIMEDIA ] CLINICAL PHARMACOLOGY Meclizine Hydrochloride is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs .
It has a marked effect in blocking the vasodepressor response to histamine , but only a slight blocking action against acetylcholine .
Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum .
INDICATIONS AND USAGE For the management of nausea and vomiting , and dizziness associated with motion sickness .
CONTRAINDICATIONS Meclizine Hydrochloride is contraindicated in individuals who have shown a previous hypersensitivity to it .
WARNINGS Since drowsiness may , on occasion , occur with use of this drug , patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery .
Patients should avoid alcoholic beverages while taking this drug .
Due to its potential anticholinergic action , this drug should be used with caution in patients with asthma , glaucoma or enlargement of the prostate gland .
PRECAUTIONS PREGNANCY , Teratogenic Effects Pregnancy Category B . Reproduction studies in rats have shown cleft palates at 25 - 50 times the human dose .
Epidemiological studies in pregnant women , however , do not indicate that medicine increases the risk of abnormalities when administered during pregnancy .
Despite the animal findings , it would appear that the possibility of fetal harm is remote .
Nevertheless , meclizine , or any other medication , should be used during pregnancy only if clearly necessary .
Pediatric Use Clinical studies establishing safety and effectiveness in children have not been done ; therefore , usage is not recommended in children under 12 years of age .
ADVERSE REACTIONS Drowsiness , dry mouth and , on rare occasions , blurred vision have been reported .
DOSAGE AND ADMINISTRATION Motion Sickness The initial dose of 25 to 50 mg of Meclizine HCI should be taken one hour prior to travel for protection against motion sickness .
Thereafter , the dose may be repeated every 24 hours for the duration of the journey .
HOW SUPPLIED Meclizine HCI Tablets , USP are available in the following strengths and package sizes : 25 mg ( Yellow , oval - shaped , scored , debossed with TL121 ) Bottles of 10 NDC 63187 - 996 - 10 Bottles of 20 NDC 63187 - 996 - 20 Bottles of 30 NDC 63187 - 996 - 30 Bottles of 60 NDC 63187 - 996 - 60 Bottles of 90 NDC 63187 - 996 - 90 Store at 20 - 25 ° C ( 68 - 77 ° F ) ( See USP Controlled Room Temperature ] .
Manufactured By : Jubilant Cadista Pharmaceuticals Inc .
Salisbury , MD 21801 , USA .
Repackaged by : Proficient Rx LP Thousand Oaks , CA 91320 Revised 03 / 11 PRINCIPAL DISPLAY PANEL [ MULTIMEDIA ] NDC 63187 - 996 - 20 Meclizine Hydrochloride Tablets , USP 25 mg 20 Tablets Rx Only Each tablet Contains 25 mg of meclizine HCl DOSAGE AND USE See accompanying prescribing information MOTION SICKNESS : 25 mg to 50 mg daily .
Dispense in tight , light - resistant containers ( USP ) .
Store at 20 - 25 ° C ( 68 - 77 ° F ) [ See USP Controlled Room Temperature ] .
[ MULTIMEDIA ]
